IntraLase to Unveil 30 kHz FS Laser at ASCRS; Delivers Twice the Speed

IntraLase to Unveil 30 kHz FS Laser at ASCRS; Delivers Twice the Speed for Faster Procedure Time, Tighter Spot Placement and Lower Energy

    Business Editors/Health/Medical Writers
    ASCRS 2005
    Booth #1005

    WASHINGTON--(BUSINESS WIRE)--April 12, 2005--IntraLase Corp. (NASDAQ:ILSE) today announced it will introduce its IntraLase FS30(TM) Laser this week at the annual meeting of the American Society for Cataract and Refractive Surgery (ASCRS). The new laser and upgrade for existing IntraLase customers increases the speed of the laser to 30 kHz from its current 15 kHz, allowing for faster procedure time, tighter spot placement and lower energy.
    "As a surgeon, it's exciting to witness technology not only driving innovation but also supporting the continued improvement in visual outcomes," said Dan B. Tran, M.D., Coastal Vision Medical Group in Southern California. "The IntraLase FS30 laser enables an optimal stromal bed to be created for the refractive procedure that follows which, as new clinical data confirms, is resulting in superior visual outcomes. Patient time under the laser has decreased thus enhancing clinical performance."
    The IntraLase(R) FS laser was commercially introduced in 2002 as the first laser available for creating corneal flaps. The laser's unsurpassed precision has now extended its use to new therapeutic applications, specifically the treatment of diseased corneas. The IntraLase laser is so uniquely sensitive to corneal physiology that it is also approved for anterior lamellar keratoplasty and intrastromal ring implantation surgeries, which like LASIK benefit from customized architecture and unsurpassed accuracy.
    "We are excited to introduce the advanced capabilities of this new technology," said Robert J. Palmisano, president and chief executive officer of IntraLase Corp. "The IntraLase FS30 makes our ultra-fast femtosecond laser even faster, delivering on our promise of continued innovation. This advancement comes on the heels of new research showing the previously overlooked importance of the corneal flap to LASIK outcomes, demonstrating a causal relationship between the IntraLase laser and the visual outcome of the procedure."

    Key benefits of the IntraLase FS30 laser include:

--	Faster Procedure Time: The IntraLase process from start to finish takes just under 30 seconds, on average. This increased speed of the laser decreases suction time for enhanced safety and patient comfort, and expedites patient throughput.
--	Tighter Spot Placement: Produces superior dissection quality and corneal interface and facilitates flap elevation.
--	Lower Energy: Diminishes the potential for post-operative inflammatory response.

    Dr. Tran added, "The IntraLase FS30 laser maximizes surgical confidence by allowing the surgeon to program specific parameters for uniformly thin and reproducible corneal results to better predict the precision and preserve the stroma."
    For more information on the IntraLase FS30 laser or to view a live demonstration, please visit IntraLase at ASCRS booth #1005. Podium presentation schedule is available at www.IntraLaseFS30.com (for editorial use only).

    About IntraLase Corp.

    IntraLase (NASDAQ:ILSE) designs, develops and manufactures an ultra-fast laser, related software and disposable devices used to create a corneal flap, the first step in LASIK surgery for the correction of vision. The company's products improve the safety, precision and visual results of LASIK procedures by providing a computer-controlled laser solution in place of the hand-held mechanical, metal-bladed microkeratome traditionally used to create corneal flaps. IntraLase lasers are also used in surgical approaches to the treatment of diseased corneas. The company's lasers and disposable per procedure patient interfaces are presently marketed throughout the United States and 17 other countries. IntraLase has headquarters and manufactures its products in Irvine, Calif. For additional information, visit the company's Web site: www.intralase.com.

    Forward-Looking Statements:

    Statements contained in this press release that are not historical information are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "believe," "expect," "anticipate," "intend," "plan," "estimate," "project," or words of similar meaning, or future or conditional verbs such as "will," "would," "should," "could," or "may." Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected or implied. Those risks and uncertainties include, but are not limited to: the degree of continued acceptance of LASIK surgery; the extent of adoption of our product offering by LASIK surgeons; general economic conditions; changes in federal tax laws governing the ability of potential LASIK patients to use pre-tax dollars to pay for LASIK surgery; the scope of government regulation applicable to our products; patients' willingness to pay for LASIK surgery; our ability to compete against our competitors; the occurrence and outcome of product liability suits against us; our ability to adequately protect our intellectual property; whether we become subject to claims of infringement or misappropriation of the intellectual property rights of others; the continued availability of supplies from single-source suppliers and manufacturers of our key laser components; the ability of our managers, operations and facilities to manage our growth; the success of our expansion into markets outside the United States; whether we lose any of our key executives or fail to attract qualified personnel; or if our new products or applications fail to become commercially viable.
    Certain of these risks and uncertainties, in addition to other risks, are more fully described in the company's final 424(b)(4) prospectus, as filed with the Securities and Exchange Commission on Oct. 7, 2004.
    These forward-looking statements are made only as of the date of this press release, and the company assumes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

--30--SE/np*

CONTACT: IntraLase Corp. Shelley B. Thunen, 949-859-5230, ext. 196 sthunen@intralase.com or Financial Relations Board Marilyn Windsor, 702-515-1260 mwindsor@financialrelationsboard.com

KEYWORD: CALIFORNIA DISTRICT OF COLUMBIA INDUSTRY KEYWORD: MEDICAL MEDICAL DEVICES SOFTWARE TRADESHOW PRODUCT SOURCE: IntraLase Corp.

Copyright Business Wire 2005